Inter Partes Review Proceedings
PTAB Portal
IPR Case No(s):
U.S. Patent No.
9,732,149 (Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement)
Patent Owner
Alexion Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co. Ltd.
§ 102 Challenge
Y: Claim 1
Claim Types Challenged Under § 102
Composition of Matter
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claim 1
Claim Types Challenged Under § 103
Composition of Matter
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
9,718,880 (Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement)
Patent Owner
Alexion Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co. Ltd.
§ 102 Challenge
Y: Claim 2
Claim Types Challenged Under § 102
Formulation
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1-3
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
9,725,504 (Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement)
Patent Owner
Alexion Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co. Ltd.
§ 102 Challenge
Y: Claims 1-5, 7-10
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1-10
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
10,590,189 (Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement)
Patent Owner
Alexion Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co. Ltd.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-8
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
10,703,809 (Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement)
Patent Owner
Alexion Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co. Ltd.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-29
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending